Abstract: A flange part 31b is provided on a vertical surface 31a on the plate member PM of the front-rear swing part 3, the flange part 31b has a guide surface 31b1 extending to lateral direction and moving the rolling body 45 in the longitudinal direction, a lateral direction dimension of the guide surface 31b1 is greater than a thickness of the plate member PM, the flange part 31b and the portion of the plate member PM forming the vertical surface 31a around the flange part 31b are integrally formed of metal; and the flange part 31b has a shape that goes around the circumference of the guide hole 34 opened in the vertical surface 31a, and then, the rolling body 45 are provided independently to the left and right, to be able to a roll along the guide surface 31b1.

Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.

Abstract: It is an object of the present invention to provide an antibody binding to CDH6 and having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody, the antibody-drug conjugate or the pharmaceutical product, and the like. The present invention provides an anti-CDH6 antibody having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.

Abstract: An anti-SIRP? antibody that can be used as a tumor agent and an anti-tumor agent comprising the antibody as an active ingredient. An antibody that binds specifically to human SIRP? to inhibit binding of human SIRP? to CD47.

Abstract: The present invention provides an EndoS mutant enzyme having an amino acid sequence of EndoS D233Q and further having a particular additional mutation and exhibiting a reduced hydrolysis activity, in comparison with the activity of EndoS D233Q, to an N-linked sugar chain (N297-linked sugar chain) linked to Asn at position 297 in IgG and a gene encoding the same.

Abstract: The present invention provides a pharmaceutical composition comprising an antibody which binds specifically to human TLR7 or monkey TLR7 and does not bind to mouse TLR7 or rat TLR7, and has an activity of inhibiting a function of human TLR7 or monkey TLR7, and the like.

Abstract: It is an object of the present invention to provide an antibody specifically binding to GPR20-positive tumor cells such as GIST, a pharmaceutical product comprising the antibody and having therapeutic effects on a tumor, a method for treating a tumor using the aforementioned pharmaceutical product, and the like. It is another object of the present invention to provide an anti-GPR20 antibody having internalization activity, an antibody-drug conjugate containing the antibody, and the like.

Abstract: It is an object of the present invention to provide an antibody specifically binding to GPR20-positive tumor cells such as GIST, a pharmaceutical product comprising the antibody and having therapeutic effects on a tumor, a method for treating a tumor using the aforementioned pharmaceutical product, and the like. It is another object of the present invention to provide an anti-GPR20 antibody having internalization activity, an antibody-drug conjugate containing the antibody, and the like.

Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.

Abstract: A chair is realized which takes specific measures to suppress movement of a seat in a front-rear direction when the seat swings in the front-rear and the left-right directions with respect to a support base. For the purpose, the chair wherein a seat 5 swings in the front-rear and left-right directions with respect to a support base 2, the chair is configured such that swinging of the seat 5 in front-rear direction with respect to the support base 2 is capable of being suppressed at one or a plurality of predetermined positions, or arbitrary position via operation of operation member 152.

Abstract: A flange part 31b is provided on a vertical surface 31a on the plate member PM of the front-rear swing part 3, the flange part 31b has a guide surface 31b1 extending to lateral direction and moving the rolling body 45 in the longitudinal direction, a lateral direction dimension of the guide surface 31b1 is greater than a thickness of the plate member PM, the flange part 31b and the portion of the plate member PM forming the vertical surface 31a around the flange part 31b are integrally formed of metal; and the flange part 31b has a shape that goes around the circumference of the guide hole 34 opened in the vertical surface 31a, and then, the rolling body 45 are provided independently to the left and right, to be able to a roll along the guide surface 31b1.

Abstract: [Problem] Provided is a chair capable of changing an operation of a movable part between allowed and suppressed states, without causing an up-down movement of a seat or without requiring a complicated structure relying on a back. [Solution] For that purpose, a weight-receiving part 50, the height position of which changes due to a person sitting on a seat surface, is provided on a seat 5, the change of the height position is mechanically transmitted to a control mechanism 8X configured to control an operation of a front-rear swing part 3 being the movable part, and the control mechanism 8X changes an operation of the front-rear swing part-3 being the movable part between allowed and suppressed states.

Abstract: It is an object of the present invention to provide an antibody binding to CDH6 and having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody-drug conjugate and having therapeutic effects on a tumor, a method for treating a tumor using the antibody, the antibody-drug conjugate or the pharmaceutical product, and the like. The present invention provides an anti-CDH6 antibody having internalization activity, an antibody-drug conjugate of the antibody and a drug having antitumor activity, a pharmaceutical product comprising the antibody or the antibody-drug conjugate, and a method for treating a tumor.

Abstract: To provide a novel antibody. Provided is a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.

Abstract: To provide a novel antibody. Provided is a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.

Abstract: In view of various movement of a seated person, when giving the left-right swinging operation to the seat in the non-conventional aspect, a chair configured such that the back can perform a new movement suitable for the left-right movement of the seat and return to the predetermined position when the seated person leaves a seat, is realized. For the purpose, a back 6 is arranged behind a seat 5, and the back 6 has an operation mechanism 6M turning-movably supporting the load received from a seated person in a left-right direction in a front view, and when the load is applied, at least a part of guide part 65a, 66a of the operation mechanism 6M is separated and the back moves freely, and when the applied load is removed, the back automatically returns to the neutral position along the guide part 65a, 66a.

Abstract: It is an object of the present invention to provide an anti-GPR20 antibody that can be used in the detection of GPR20, a reagent for GPR20 detection comprising the antibody, a reagent for diagnosis or a composition for testing of a disease related to the expression of GPR20, etc. The present invention provides an antibody specifically binding to a peptide comprising the amino acid sequence at amino acid positions 1 to 48 in SEQ ID NO: 1, or an antigen-binding fragment of the antibody, a chimeric antibody of the antibody, a rabbit type antibody of the antibody, etc. The present invention also provides a composition comprising the antibody, etc.

Abstract: This application provides: an antibody which specifically binds to an ALK2 protein and has an activity of inhibiting BMP signal transduction mediated by ALK2; a method for producing the antibody; and a pharmaceutical composition comprising the antibody, for treating and/or preventing ectopic ossification and/or bone dysplasia, anemia, or diffuse intrinsic pontine glioma (DIPG).

Abstract: The present disclosure provides a novel antibody that binds to human GPRC5D; a molecule with human GPRC5D binding activity, which comprises the antibody; and an anti-tumor pharmaceutical composition comprising the antibody or the molecule as an active.

Abstract: The present invention provides a novel antibody binding to human CD3, and a molecule having antigen binding activity that includes the antibody. The present invention provides a novel antibody binding to human CD3, a molecule having antigen binding activity that includes the antibody, and a pharmaceutical composition having cytotoxic activity that includes the antibody or the molecule as an active ingredient.